Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01998139 · ClinicalTrials.gov registry record
Endothelial Microparticles as a Biomarker for Diagnosis and Prognosis in Early Sepsis
A clinical trial of Systemic Inflammatory Response Syndrome, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 137
- Enrollment target
- 2
- Study locations
NCT01998139 is a study of Systemic Inflammatory Response Syndrome that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 137 participants, below the 570-participant average among 5 other Systemic Inflammatory Response Syndrome trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01998139, a study of Systemic Inflammatory Response Syndrome, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 137 participants
- Enrollment target
- 2
- Study locations
Study Summary
Sepsis is a major global health problem, leading to substantial morbidity and mortality despite medical care. The initial diagnosis of sepsis is a clinical challenge, as it is based on nonspecific systemic criteria. Excessive endothelial activation is a cardinal feature of sepsis and contributes to microvascular leak, edema, circulatory shock and organ failure. Activated endothelial cells shed endothelial microparticles (EMPs) which can be measured in plasma and are found at low levels in healthy subjects. Elevated EMPs have been reported in sepsis, but whether their effect is beneficial or deleterious is unclear. In this context, we hypothesize that circulating EMP levels can be assessed as a biomarker differentiating sepsis from non-sepsis critical illness. This may also suggest that EMP levels correlate with 30-day mortality. We propose to measure circulating EMPs at ICU admission in subjects with suspected sepsis. Final diagnoses will be adjudicated using standard criteria and 30-day mortality ascertained. Subjects determined not to have sepsis will serve as the control group. EMP levels will be correlated with diagnosis to ascertain the utility of EMP levels as a diagnostic biomarker for sepsis. For those subjects with proven sepsis, EMP levels will be correlated to 30-day mortality to assess EMP level as a prognostic marker in sepsis.
Conditions Studied
Study Locations (2)
New York
- Weill Cornell Medical College - New York
Other
- Hamad Medical Corporation - Doha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2013-07 |
| Est. Completion | 2019-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01998139
The ClinicalTrials.gov registry entry for NCT01998139 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 570-participant average among 5 other Systemic Inflammatory Response Syndrome trials with a reported enrollment target (76% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Inflammatory Response Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT01998139 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Other.
Frequently Asked Questions
What is clinical trial NCT01998139 about?
NCT01998139 is a clinical study titled "Endothelial Microparticles as a Biomarker for Diagnosis and Prognosis in Early Sepsis". Sepsis is a major global health problem, leading to substantial morbidity and mortality despite medical care. The initial diagnosis of sepsis is a clinical challenge, as it is based on nonspecific systemic criteria. Excessive endothelial activation is a cardinal feature of sepsis and contributes to ...
What is the current status of trial NCT01998139?
This trial is currently completed. The enrollment target is 137 participants. The study started on 2013-07. Estimated completion is 2019-02.
What conditions does trial NCT01998139 study?
This clinical trial studies the following conditions: Systemic Inflammatory Response Syndrome.
Who is sponsoring clinical trial NCT01998139?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01998139 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Inflammatory Response Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Modulation of Molecular Fingerprinting in Pediatric Sepsis
RECRUITING
-
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
RECRUITING · Phase 4
-
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
RECRUITING
-
A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS
COMPLETED · Phase 2
-
Feeding the Critically Ill During Phases of Altered Redox Status
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.